Salvesen HB - Search Results

1

Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.

Wik E, Ræder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB. Wik E, et al. Among authors: salvesen hb. Clin Cancer Res. 2013 Mar 1;19(5):1094-105. doi: 10.1158/1078-0432.CCR-12-3039. Epub 2013 Jan 14. Clin Cancer Res. 2013. PMID: 23319822

2

High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.

Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, Hoivik EA, Wik E, Halle MK, Øyan AM, Kalland KH, Werner HM, Trovik J, Salvesen H. Krakstad C, et al. PLoS One. 2012;7(12):e52795. doi: 10.1371/journal.pone.0052795. Epub 2012 Dec 27. PLoS One. 2012. PMID: 23300780 Free PMC article.

3

Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study.

Stefansson I, Akslen LA, MacDonald N, Ryan A, Das S, Jacobs IJ, Salvesen HB. Stefansson I, et al. Among authors: salvesen hb. Clin Cancer Res. 2002 Jan;8(1):138-43. Clin Cancer Res. 2002. PMID: 11801550

4

Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma.

Salvesen HB, Stefansson I, Kalvenes MB, Das S, Akslen LA. Salvesen HB, et al. Cancer. 2002 Apr 15;94(8):2185-91. doi: 10.1002/cncr.10434. Cancer. 2002. PMID: 12001116 Free article.

5

Molecular pathogenesis and prognostic factors in endometrial carcinoma.

Salvesen HB, Akslen LA. Salvesen HB, et al. APMIS. 2002 Oct;110(10):673-89. doi: 10.1034/j.1600-0463.2002.1101001.x. APMIS. 2002. PMID: 12583434 Review.

6

Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer.

Stefansson IM, Salvesen HB, Akslen LA. Stefansson IM, et al. Among authors: salvesen hb. J Clin Oncol. 2004 Apr 1;22(7):1242-52. doi: 10.1200/JCO.2004.09.034. J Clin Oncol. 2004. PMID: 15051772

7

Low frequency of BRAF and CDKN2A mutations in endometrial cancer.

Salvesen HB, Kumar R, Stefansson I, Angelini S, MacDonald N, Smeds J, Jacobs IJ, Hemminki K, Das S, Akslen LA. Salvesen HB, et al. Int J Cancer. 2005 Jul 20;115(6):930-4. doi: 10.1002/ijc.20702. Int J Cancer. 2005. PMID: 15723290 Free article.

8

Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients.

Stefansson IM, Salvesen HB, Akslen LA. Stefansson IM, et al. Among authors: salvesen hb. Int J Cancer. 2006 Mar 1;118(5):1227-33. doi: 10.1002/ijc.21415. Int J Cancer. 2006. PMID: 16152605 Free article.

9

Vascular proliferation is important for clinical progress of endometrial cancer.

Stefansson IM, Salvesen HB, Akslen LA. Stefansson IM, et al. Among authors: salvesen hb. Cancer Res. 2006 Mar 15;66(6):3303-9. doi: 10.1158/0008-5472.CAN-05-1163. Cancer Res. 2006. PMID: 16540684

10

HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.

Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB. Engelsen IB, et al. Among authors: salvesen hb. Int J Oncol. 2008 Feb;32(2):307-16. Int J Oncol. 2008. PMID: 18202752

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

229 results

Search Page